HTR1D
| Official symbol: | HTR1D |
| Full name: | 5-hydroxytryptamine receptor 1D |
| Location: | 1p36.12 |
| Also known as: | HT1DA, HTRL, 5-HT1D, RDC4 |
| Entrez ID: | 3352 |
| Ensembl ID: | ENSG00000179546 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| Recurrently deleted in 1 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 0 |
|
|
|
| |
|
|
|
| Functional class: | G protein-coupled receptor |
| JensenLab PubMed score: | 350.78 (Percentile rank: 87.82%) |
| PubTator score: | 184.96 (Percentile rank: 85.10%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
